Publication | Open Access

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Breast OncologyMedicineCleopatra StudyPathologyBreast CancerCancer TreatmentOncologyRadiation OncologyMolecular OncologyOverall Survival Results